GenVec, Novartis ink clinical trials supply deal

GenVec could receive approximately $13 million over four years after inking an agreement with Novartis through which it will manufacture clinical trial material for up to two lead candidates. The two companies are partnered on clinical programs for hearing loss and balance disorders. GenVec release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.